Forecasting the Future of Cardiovascular Disease in the United States

Heidenreich, Paul A

Trogdon, Justin G

Khavjou, Olga A

Butler, Javed

Dracup, Kathleen

Ezekowitz, Michael D

Finkelstein, Eric Andrew

Hong, Yuling

Johnston, S Claiborne

Khera, Amit

Lloyd-Jones, Donald M

Nelson, Sue A

Nichol, Graham

Orenstein, Diane

Wilson, Peter WF

Woo, Y Joseph

American Heart Association Advocacy Coordinating Committee

Stroke Council

Council on Cardiovascular Radiology and Intervention

Council on Clinical Cardiology

Council on Epidemiology and Prevention

Council on Arteriosclerosis

Thrombosis and Vascular Biology

Council on Cardiopulmonary

Critical Care

Perioperative and Resuscitation

Council on Cardiovascular Nursing

Council on the Kidney in Cardiovascular Disease

Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research

2012-10-30T19:24:24Z

2012-10-30T19:24:24Z

2011-03

Background—Cardiovascular disease (CVD) is the leading cause of death in the United States and is responsible for 17% of national health expenditures. As the population ages, these costs are expected to increase substantially. Methods and Results—To prepare for future cardiovascular care needs, the American Heart Association developed methodology to project future costs of care for hypertension, coronary heart disease, heart failure, stroke, and all other CVD from 2010 to 2030. This methodology avoided double counting of costs for patients with multiple cardiovascular conditions. By 2030, 40.5% of the US population is projected to have some form of CVD. Between 2010 and 2030, real (2008$) total direct medical costs of CVD are projected to triple, from $273 billion to $818 billion. Real indirect costs (due to lost productivity) for all CVD are estimated to increase from $172 billion in 2010 to $276 billion in 2030, an increase of 61%. Conclusions—These findings indicate CVD prevalence and costs are projected to increase substantially. Effective prevention strategies are needed if we are to limit the growing burden of CVD.

Heidenreich, P. A., J. G. Trogdon, et al. (2011). "Forecasting the Future of Cardiovascular Disease in the United States." Circulation 123(8): 933-944.

https://hdl.handle.net/10161/5962

Ovid Technologies (Wolters Kluwer Health)

10.1161/CIR.0b013e31820a55f5

Circulation

AHA Scientific Statements

cardiovascular diseases

forecasting

US costs

cost analysis

Forecasting the Future of Cardiovascular Disease in the United States

Journal article

8

123

933

944